Tina Shih, PhD, of The University of Texas MD Anderson Cancer Center, discusses the rising cost-sharing requirement from private insurance, which has worsened the financial burden for patients with cancer. She believes that cost-containment policies alone may not be enough to ease this hardship.
Aakash Desai, MPH, MD, of the Mayo Clinic in Rochester, Minnesota, talks about the urgent need for drug pricing reform, given the average expenditure of Medicare part D, and the ultimate out-of-pocket costs for patients with cancer. The promise of precision oncology will fail, says Dr. Desai, if we fail to bring the right drugs to the right patient at the right time, with the right price.
Sarah S. Mougalian, MD, of Yale Cancer Center, discusses the increasingly common problem of long wait times for access to oncology care. Her team developed a next-day access program in several of Yale’s oncology services, which was well received by patients and decreased the time to first visit.
Divya Gupta, MD, of the Stanford Cancer Center, discusses an intervention utilizing a computer model and lay care coaches to improve advance care planning conversations with patients who have metastatic cancer. The study, Dr. Gupta reports, showed a trend toward less intensive care for patients at the end of life.
Katherine E. Reeder-Hayes, MD, MBA, of the University of North Carolina at Chapel Hill, discusses the timeliness of breast cancer care for Black women compared with non-Black women in North Carolina. Her data showed that greater geographic variation exists in the timeliness of breast cancer care for Black women, with regions surrounding larger urban centers having the largest disparities.
Jenny Jing Xiang, MD, of Yale University School of Medicine, discusses a universal, standardized clinical trial prescreening protocol, which streamlined research recruitment and was associated with yearly increases in patient enrollment at the Veterans Administration (VA) Connecticut Cancer Center. The Center became the top-accruing VA site for National Cancer Institute–sponsored trials and was ranked in the top 10 enrolling sites nationally for VA and non-VA hospitals.
